HIMS:NYE-Hims Hers Health Inc (USD)

COMMON STOCK | Household & Personal Products |

Last Closing

USD 53.36

Change

-1.47 (-2.68)%

Market Cap

USD 11.63B

Volume

0.03B

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-27 )

Largest Industry Peers for Household & Personal Products

Symbol Name Price(Change) Market Cap
UL Unilever PLC ADR

+0.27 (+0.43%)

USD 156.80B
KMB Kimberly-Clark Corporation

+1.16 (+0.81%)

USD 46.97B
CHD Church & Dwight Company Inc

+0.18 (+0.18%)

USD 23.63B
CLX The Clorox Company

+0.83 (+0.64%)

USD 16.80B
ELF ELF Beauty Inc

+21.34 (+23.58%)

USD 4.73B
COTY Coty Inc

+0.22 (+4.61%)

USD 4.17B
SPB Spectrum Brands Holdings Inc

+1.52 (+2.67%)

USD 1.63B
EPC Edgewell Personal Care Co

-0.04 (-0.14%)

USD 1.38B
PZC PIMCO California Municipal Inc..

+0.02 (+0.32%)

USD 0.63B
YSG Yatsen Holding

+0.13 (+2.45%)

USD 0.45B

ETFs Containing HIMS

THNR Amplify ETF Trust 7.42 % 0.00 %

+0.10 (+-3.42%)

USD 2.82M
EDOC:LSE Global X Telemedicine & D.. 6.38 % 0.00 %

+0.06 (+-3.42%)

USD 4.27M
EDOG:LSE Global X Telemedicine & D.. 6.38 % 0.00 %

+0.03 (+-3.42%)

USD 0.30M
EDOC:AU 4.99 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 4.61 % 0.00 %

+0.27 (+-3.42%)

USD 3.28M
DDOC:F Global X Telemedicine & D.. 4.59 % 0.00 %

+0.09 (+-3.42%)

N/A
EDOC:SW Global X Telemedicine & D.. 4.40 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 4.27 % 0.00 %

+0.23 (+-3.42%)

USD 4.76M
HIMZ Defiance Daily Target 2X .. 4.27 % 0.00 %

-1.24 (-3.42%)

N/A
FCUS Pinnacle Focused Opportun.. 4.02 % 0.00 %

-0.20 (-3.42%)

USD 0.03B
FDOC:LSE 3.42 % 0.00 %

N/A

N/A
XHS SPDR® S&P Health Care Se.. 3.36 % 0.35 %

+0.12 (+-3.42%)

USD 0.09B
FDHT Fidelity Covington Trust .. 2.80 % 0.00 %

+0.19 (+-3.42%)

USD 8.09M
FLDZ Listed Funds Trust 0.70 % 0.00 %

+0.04 (+-3.42%)

USD 3.91M
ITWO Proshares Russell 2000 Hi.. 0.44 % 0.00 %

-0.03 (-3.42%)

USD 0.05B
UWM ProShares Ultra Russell20.. 0.34 % 0.95 %

+0.20 (+-3.42%)

USD 0.30B
BFOR Barron's 400 ETF 0.00 % 0.65 %

+0.19 (+-3.42%)

USD 0.15B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.37 (-3.42%)

N/A
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

-0.06 (-3.42%)

USD 0.02B
IBUY Amplify Online Retail ETF 0.00 % 0.65 %

-0.10 (-3.42%)

USD 0.14B
JSML Janus Henderson Small Cap.. 0.00 % 0.50 %

-0.03 (-3.42%)

USD 0.17B
PSC Principal U.S. Small-Cap .. 0.00 % 0.38 %

+0.05 (+-3.42%)

USD 0.73B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

+0.06 (+-3.42%)

USD 16.85B
AFSM First Trust Active Factor.. 0.00 % 0.00 %

+0.12 (+-3.42%)

USD 0.03B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

-0.02 (-3.42%)

N/A
BUZZ VanEck Social Sentiment E.. 0.00 % 0.00 %

-0.27 (-3.42%)

USD 0.06B
DFAS Dimensional U.S. Small Ca.. 0.00 % 0.00 %

+0.15 (+-3.42%)

USD 9.63B
RSSL:AU Global X Russell 2000 Etf 0.00 % 0.00 %

+0.17 (+-3.42%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Household & Personal Products) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 120.68% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 120.68% 100% F 100% F
Trailing 12 Months  
Capital Gain 179.37% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.37% 100% F 99% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 58.26% 94% A 96% N/A
Dividend Return 58.26% 94% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 103.48% 6% D- 7% C-
Risk Adjusted Return 56.30% 94% A 71% C-
Market Capitalization 11.63B 69% C- 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.